Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis
- 16 February 2016
- journal article
- other
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (10) , 2464-2467
Abstract
Ruxolitinib, a Janus kinase 1 and 2 (JAK1/2) inhibitor, is the only approved drug for the treatment of intermediate- or high-risk myelofibrosis.[1] In the phase 3 registration trials, ruxolitinib d...Keywords
This publication has 10 references indexed in Scilit:
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisHaematologica, 2015
- Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?Expert Review of Hematology, 2015
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-IHaematologica, 2015
- Mathematical Modeling of Patient-Level Hemoglobin Delineates Ruxolitinib’s Complex Mechanism of Action and Quantifies Anemia RiskBlood, 2014
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosisBlood, 2013
- Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosingJournal of Hematology & Oncology, 2013
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for MyelofibrosisNew England Journal of Medicine, 2012
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for MyelofibrosisNew England Journal of Medicine, 2012
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)Blood, 2010
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and TreatmentBlood, 2009